Clinical trial of lopinavir-ritonavir (brand name: Kaletra) shows no benefit beyond standard of care for patients with severe novel coronavirus infection
As the search continues for treatments, cure, or vaccine for novel coronavirus (COVID-19) continues, a new article published on March 18, 2020, in the New England Journal of Medicine says that a two HIV drug combo of lopinavir-ritonavir (brand name: Kaletra) fails to provide benefit beyond standard of care in trial.
“In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir–ritonavir treatment beyond standard care. Future trials in patients with severe illness may help to confirm or exclude the possibility of a treatment benefit.”
Full article available here: https://www.nejm.org/doi/full/10.1056/NEJMoa2001282